GeneDX Reports Weak Q1 Results and Cuts Full-Year Guidance
GeneDX's first-quarter results fell significantly below expectations, leading to a sharp decline in its stock price. The company reported a non-GAAP loss of $0.28 per share and sales of $102.3 million, missing analyst estimates. GeneDX also reduced its full-year sales forecast, intensifying investor concerns.
Topics: Biotech Earnings Guidance Cut Sales Forecast Stock Price Movement